Harmony looks to buy rare disease drug developer in deal worth up to $200M

Paul Schloesser

Associate Editor

Harmony Biosciences is paying $60 million in cash to get its hands on Zynerba Pharmaceuticals and a therapy it’s developing to treat two rare diseases …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Harmony looks to buy rare disease drug developer in deal worth up to $200M

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Har­mo­ny looks to buy rare dis­ease drug de­vel­op­er in deal worth up to $200M

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Harmony looks to buy rare disease drug developer in deal worth up to $200M